EMERGENT BIOSOLUTIONS INC

NYSE: EBS (Emergent BioSolutions Inc.)

Last update: 02 Oct, 8:19PM

9.19

0.00 (0.00%)

Previous Close 9.19
Open 9.18
Volume 617,478
Avg. Volume (3M) 1,155,493
Market Cap 490,296,576
Price / Earnings (TTM) 3.51
Price / Earnings (Forward) 2.33
Price / Sales 0.620
Price / Book 0.910
52 Weeks Range
4.02 (-56%) — 12.73 (38%)
Earnings Date 10 Nov 2025
Profit Margin -13.63%
Operating Margin (TTM) 22.68%
Diluted EPS (TTM) -2.58
Quarterly Revenue Growth (YOY) -26.00%
Quarterly Earnings Growth (YOY) 655.60%
Total Debt/Equity (MRQ) 121.71%
Current Ratio (MRQ) 6.32
Operating Cash Flow (TTM) 110.10 M
Levered Free Cash Flow (TTM) 91.12 M
Return on Assets (TTM) -1.61%
Return on Equity (TTM) -21.63%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Mixed
Drug Manufacturers - Specialty & Generic (Global) Bullish Mixed
Stock Emergent BioSolutions Inc. Mixed Bullish

AIStockmoo Score

0.9
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators 4.0
Average 0.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
EBS 490 M - 3.51 0.910
ELAN 5 B - 15.35 1.50
AMRX 3 B - 1,025.00 -
PRGO 3 B 2.64% - 0.680
ZTS 64 B 0.99% 24.76 13.04
TAK 45 B 4.61% 50.61 0.980

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 2.83%
% Held by Institutions 67.20%
52 Weeks Range
4.02 (-56%) — 12.73 (38%)
Median 15.00 (63.22%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 03 Sep 2025 15.00 (63.22%) Buy 7.83

No data within this time range.

Date Type Details
29 Oct 2025 Announcement Emergent BioSolutions Reports Third Quarter 2025 Financial Results
28 Oct 2025 Announcement Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
08 Oct 2025 Announcement Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
24 Sep 2025 Announcement Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
19 Sep 2025 Announcement Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
15 Sep 2025 Announcement Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
09 Sep 2025 Announcement Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
02 Sep 2025 Announcement Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
29 Aug 2025 Announcement Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
27 Aug 2025 Announcement Emergent BioSolutions to Participate in Upcoming Investor Conferences
21 Aug 2025 Announcement Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria